Company intelligence / Profile preview

Novan

Durham, North Carolina, United Statesnovanglobal.com ↗

Ownership: Public · NOVN
Employees: ~50
Development stage: NDA

Overview

Berdazimer gel was the lead asset; it reached NDA submission with a PDUFA date in early 2024 as a potential first at-home treatment for molluscum contagiosum. The broader pipeline included late-stage programs in acne and external genital warts but faced financial challenges leading to bankruptcy and asset sale to Ligand Pharmaceuticals[1][7].

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small moleculeNitric oxide-based drugs
Industry: Biotech

Drug pipeline

8 assets

berdazimer

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with academic institutions such as University of North Carolina, Pennsylvania State University, University of Alabama-BirminghamBayer-partnered Sitavig program transferred to Ligand upon acquisition

Financials

Market cap: $2.6M
Total revenue: $3M
Enterprise value: $-6.1M

Beyond the preview

Go deeper on Novan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novan.

Explore the full profile